GIM
TAK icon

Gold Investment Management’s Takeda Pharmaceutical TAK Stock Holding History

Gold Investment Management’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.7M Sell
105,849
-5,451
-5% -$90.2K 0.46% 63
2026
Q1 		$2.06M Buy
111,300
+3,018
+3% +$53K 0.64% 57
2025
Q4 		$1.69M Buy
108,282
+4,407
+4% +$63K 0.54% 62
2025
Q3 		$1.52M Buy
103,875
+3,827
+4% +$56.8K 0.51% 63
2025
Q2 		$1.54M Buy
100,048
+2,490
+3% +$36.8K 0.58% 60
2025
Q1 		$1.45M Buy
97,558
+15,411
+19% +$216K 0.61% 62
2024
Q4 		$1.09M Buy
82,147
+8,943
+12% +$123K 0.46% 68
2024
Q3 		$1.05M Buy
73,204
+1,428
+2% +$20.3K 0.44% 68
2024
Q2 		$929K Buy
71,776
+1,453
+2% +$19.2K 0.39% 73
2024
Q1 		$977K Buy
70,323
+659
+0.9% +$9.58K 0.39% 70
2023
Q4 		$994K Buy
+69,664
New +$988K 0.43% 70

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Gold Investment Management's TAK Position: Q2 2026 in Review

Gold Investment Management reduced its Takeda Pharmaceutical (TAK) stake by 4.9% in Q2 2026, selling an estimated $90.2K and leaving 105,849 shares worth $1.7M. The position accounts for 0.46% of the portfolio, ranked #63.

Gold Investment Management first reported a position in TAK in Q4 2023 and has held it in 11 quarters since. The position peaked at $2.06M in Q1 2026. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Gold Investment Management held 105,849 shares of Takeda Pharmaceutical worth $1.7M as of Q2 2026.
  • Gold Investment Management sold 5,451 Takeda Pharmaceutical shares in Q2 2026, an estimated $90.2K.
  • Takeda Pharmaceutical made up 0.46% of Gold Investment Management's portfolio in Q2 2026, its #63 holding.
  • Gold Investment Management first reported a position in Takeda Pharmaceutical in Q4 2023 and has held it in 11 quarters since.
  • Gold Investment Management's Takeda Pharmaceutical position peaked at $2.06M in Q1 2026.
  • 376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Gold Investment Management's 13F filing for Q2 2026, filed 6 Aug 2026.